Transforming healthcare by unlocking the hidden power of blood flow data.

2013
NovaSignal is founded
2016
NovaSignal receives a $3M grant from the NIH to study traumatic brain injury and stroke
2016
The LucidTM M1 receives FDA 510(k) clearance
2017
Lucid M1 receives CE Mark approval and NovaSignal opens its first office in Europe
2017
Awarded $10M grant from the Department of Defense
2018
The NeuralBotTM receives FDA clearance, paving the way for the LucidTM Robotic System to become the first fully-automated ultrasound.
2019
The first commercial Lucid Robotic System is acquired by Houston Methodist University to monitor blood flow during open heart surgery.
2020
NovaSignal hires tech industry luminary Diane Bryant as CEO and Chairman. Corporate strategy is expanded to unlock the value of NovaSignal’s proprietary data set.

Mission

NovaSignal was founded in 2013 with the sole mission of providing greater access to critical data needed by physicians to improve the lives of their patients. Co-Founder Dr. Robert Hamilton was pursuing his Ph.D. in the Department of Neurosurgery at UCLA and it was here that he developed NovaSignal’s core technology that is in use by physicians across the world today.

Robert worked daily in the neurocritical care unit, and conducted international research in Haiti, China, and Malawi where access to medical technology was limited. It was these combined experiences that inspired him to start NovaSignal, and after he was introduced to MBA students Dan Hanchey and Leo Petrossian the NovaSignal story began!

$85M

Capital raised

$26M

Grants awarded by the National Institutes of Health, National Science Foundation, and Department of Defense

>110

Systems in use in the US and Europe

2

Received regulatory clearance on two medical devices